4 Reasons Why Buying Viking Therapeutics Stock Right Now Is a Smart Move
When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and ...
Wall Street Lunch: Viking Weight-Loss Pill Data Is Striking
Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 ...
This Pharma Stock Is Rising. The Weight-Loss Drugs Race Has Widened Beyond Lilly, Novo.
Viking says an early-stage study of its obesity pill VK2735 showed adults on the highest dosage lost 8.2% of their body ...
Stockhouse4d
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024
Despite reduction in VK2735 exposure, significant reductions in body weight were observed, with subjects reporting mean body weight change of -4.0% from baseline at Day 28 (p<0.0001). Weight loss ...
Is Viking Therepautics a Buy Now?
Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...
Viking shares jump after positive early data on oral obesity pill; Lilly, Novo drop
Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...